Cargando…
Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Neuromyelitis Optica Spectrum Disorder
Objective: To investigate the pharmacokinetics and pharmacodynamics of the approved 900/1,200 mg dosing regimen for the terminal complement component 5 (C5) inhibitor eculizumab in patients with neuromyelitis optica spectrum disorder (NMOSD). Methods: Data were analyzed from 95 patients with aquapor...
Autores principales: | Singh, Pratap, Gao, Xiang, Kleijn, Huub Jan, Bellanti, Francesco, Pelto, Ryan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597263/ https://www.ncbi.nlm.nih.gov/pubmed/34803867 http://dx.doi.org/10.3389/fneur.2021.696387 |
Ejemplares similares
-
Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis
por: Monteleone, Jonathan P. R., et al.
Publicado: (2021) -
Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: Case report
por: Chatterton, Sophie, et al.
Publicado: (2022) -
Eculizumab in the treatment of neuromyelitis optica spectrum disorder
por: Nabizadeh, Fardin, et al.
Publicado: (2023) -
Eculizumab in the Treatment of Aquaporin-4 Seronegative Neuromyelitis Optica Spectrum Disorder: A Case Report
por: Digala, Lakshmi, et al.
Publicado: (2021) -
Neuromyelitis Optica Spectrum Disorder
por: Cazzaniga, Juliana, et al.
Publicado: (2023)